What’s it take to re­cruit a top drug de­vel­op­ment ex­ec out of Gilead? Stock op­tions help, a lot

For the grow­ing ranks of pub­lic biotechs, stock op­tions are prov­ing an at­trac­tive al­lure for new ex­ec­u­tive re­cruits com­ing out of the top ranks of the world’s big bio­phar­ma com­pa­nies.

Take As­sem­bly Bio­sciences $ASMB. The hep B biotech is ex­e­cut­ing a switch-up in R&D. Their CMO, Uri Lopatin, turned in his res­ig­na­tion and As­sem­bly arranged to bring in a sea­soned de­vel­op­ment vet — Stephen Knox — from Gilead to take charge of the de­vel­op­ment group while they start a search for a new CMO. His new ti­tle: Se­nior vice pres­i­dent.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER